New antibody aims to tame rare bleeding disorder
Disease control
Not yet recruiting
This early-phase trial tests an experimental antibody called DIAG723 in 93 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The study will check if the drug is safe and how the body processes it, with…
Phase: PHASE1, PHASE2 • Sponsor: Diagonal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC